Hiren Patel

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Insulin Resistance

Top Venues

Diabetes therapy : research, treatment and education of diabetes and related disorders

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Kristina Secnik Boye, Jiat Ling Poon, Laura Fernández Landó, Hélène Sapin, Ruth Huh, Mianbo Wang, Suzanne Williamson, Hiren Patel
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6). Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (9) (2024)
Kristina Secnik Boye, Jiat Ling Poon, Laura Fernández Landó, Hélène Sapin, Ruth Huh, Mianbo Wang, Suzanne Williamson, Hiren Patel
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6). Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (9) (2024)
Kristina Secnik Boye, Jiat Ling Poon, Laura Fernández Landó, Hélène Sapin, Ruth Huh, Mianbo Wang, Suzanne Williamson, Hiren Patel
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6). Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (9) (2024)
Kristina Secnik Boye, Jiat Ling Poon, Laura Fernández Landó, Hélène Sapin, Ruth Huh, Mianbo Wang, Suzanne Williamson, Hiren Patel
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6). Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (9) (2024)
Kristina Secnik Boye, Jiat Ling Poon, Laura Fernández Landó, Hélène Sapin, Ruth Huh, Mianbo Wang, Suzanne Williamson, Hiren Patel
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6). Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Kristina S Boye, Vivian Thuyanh Thieu, Hélène Sapin, A Richey Sharrett, Laura Fernández Landó, Katelyn Brown, Ross Bray, Russell J Wiese, Hiren Patel, Angel Rodríguez, Maria Yu
Patient-Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Adie Viljoen, Kevin M Pantalone, Rodolfo J Galindo, Xuewei Cui, Ruth Huh, Andrea Hemmingway, Laura Fernández Landó, Hiren Patel
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3. Diabetes therapy : research, treatment and education of diabetes and related disorders (2023)
Hiren Patel, Kamlesh Khunti F MedSci, Helena W Rodbard, Harpreet S Bajaj, Ross Bray, Zbigniew Kindracki, Angel Rodríguez
Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials. Diabetes, obesity & metabolism (2023)
Karan Vadher, Hiren Patel, Reema Mody, Joshua A Levine, Meredith Hoog, Alice Yy Cheng, Kevin M Pantalone, Hélène Sapin
Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison. Diabetes, obesity & metabolism 24 (9) (2022)
Reema Mody, Qing Huang, Maria Yu, Ruizhi Zhao, Hiren Patel, Michael Grabner, Laura Fernández Landó
Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes, obesity & metabolism 21 (4) (2019)
Guillermo E Umpierrez, Kevin M Pantalone, Charles M Atisso, Laura Fernández Landó, Hiren Patel
Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide. Diabetes, obesity & metabolism 21 (6) (2019)
Hiren Patel, Kashif Munir, Sindee Sutherland, Chrisanthi A Karanikas, Manige Konig
Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 10 (6) (2019)